Io Therapeutics Phase II Clinical Stage and Preclinical Retinoid Compounds for Treatment of Cancers
Martin E. Sanders, M.D., Vidyasagar Vuligonda, Ph.D., March 2025
IRX4204: A Phase II Clinical Stage Third Generation RXR Nuclear Receptor Agonist for Treatment of Alzheimer’s Disease and Other Dementias
Martin E. Sanders, M.D., Vidyasagar Vuligonda, Ph.D., March 2025
IRX4204: An RXR Nuclear Receptor Agonist for Treatment of Neuroinflammatory Demyelinating Conditions Stroke, CNS Injury, MS, ALS, and Normal Aging-related Neurodegeneration
Martin E. Sanders, M.D., Vidyasagar Vuligonda, Ph.D., March 2025
IRX4204 – A Clinical Stage Potent and Selective RXR Agonist Compound for Treatment of Psoriasis and other Autoimmune Skin Diseases
Martin E. Sanders, M.D., Vidyasagar Vuligonda, Ph.D, March 2025
IRX4204 is a Phase II Clinical Stage Candidate Treatment for Disease Modification of Parkinson’s Disease
Martin E. Sanders, M.D., Vidyasagar Vuligonda, Ph.D, March 2025